Literature DB >> 8137496

Changes in type VI adenylyl cyclase isoform expression correlate with a decreased capacity for cAMP generation in the aging ventricle.

K Tobise1, Y Ishikawa, S R Holmer, M J Im, J B Newell, H Yoshie, M Fujita, E E Susannie, C J Homcy.   

Abstract

We investigated the developmental regulation of the beta-adrenergic receptor-Gs-adenylyl cyclase pathway in myocardial membranes from fetal, neonatal, adult, and mature adult rats by measuring the density of the beta-adrenergic receptor and the activities of the stimulatory guanine nucleotide-binding protein Gs and the adenylyl cyclase enzyme. Total beta-adrenergic receptor content (in femtomoles per milligram protein) was greatest in the fetal (124.4 +/- 20.5 fmol/mg) and neonatal (122.3 +/- 16.1 fmol/mg) stages and gradually decreased in the adult (90.9 +/- 8.0 fmol/mg) and mature adult (70.0 +/- 9.6 fmol/mg) stages. An equivalent pattern was seen for adenylyl cyclase activity: the basal activity of the effector enzyme or that measured in the presence of 0.1 mmol/L isoproterenol with 0.1 mmol/L Gpp(NH)p, 10 mmol/L NaF, or 0.05 mmol/L forskolin was greater in the fetus and the neonate than in the adult and the mature adult. These data suggested that decreased stimulation of the catalytic unit by Gs could be the underlying cause of diminished adenylyl cyclase activity with aging. However, quantification of Gs by reconstitution into S49 cyc- membranes (in picomoles cAMP per microgram for 10 minutes) demonstrated no significant decrease during development from fetus (1.55 +/- 0.1 pmol/microgram) to neonate (1.9 +/- 0.5 pmol/microgram) and subsequent aging to adult (2.6 +/- 0.2 pmol/micrograms) and mature adult (1.9 +/- 0.2 pmol/microgram). When Northern blot analysis was used to characterize the relative amounts of mRNA coding for Gs alpha, no significant differences were seen among the developmental stages studied.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137496     DOI: 10.1161/01.res.74.4.596

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  17 in total

1.  Pharmacological characterization of adenylyl cyclase isoforms in rabbit kidney membranes.

Authors:  Miriam Erdorf; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-29       Impact factor: 3.000

2.  Ca(2+) -stimulated basal adenylyl cyclase activity localization in membrane lipid microdomains of cardiac sinoatrial nodal pacemaker cells.

Authors:  Antoine Younes; Alexey E Lyashkov; David Graham; Anna Sheydina; Maria V Volkova; Megan Mitsak; Tatiana M Vinogradova; Yevgeniya O Lukyanenko; Yue Li; Abdul M Ruknudin; Kenneth R Boheler; Jennifer van Eyk; Edward G Lakatta
Journal:  J Biol Chem       Date:  2008-03-20       Impact factor: 5.157

3.  Oscillation of cAMP and Ca(2+) in cardiac myocytes: a systems biology approach.

Authors:  Takehisa Kamide; Satoshi Okumura; Samik Ghosh; Yoko Shinoda; Yasumasa Mototani; Yoshiki Ohnuki; Huiling Jin; Wenqian Cai; Kenji Suita; Itaru Sato; Masanari Umemura; Takayuki Fujita; Utako Yokoyama; Motohiko Sato; Kazuharu Furutani; Hiroaki Kitano; Yoshihiro Ishikawa
Journal:  J Physiol Sci       Date:  2015-01-14       Impact factor: 2.781

4.  Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.

Authors:  Douglas D Lemon; Todd R Horn; Maria A Cavasin; Mark Y Jeong; Kurt W Haubold; Carlin S Long; David C Irwin; Sylvia A McCune; Eunhee Chung; Leslie A Leinwand; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2011-04-23       Impact factor: 5.000

Review 5.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

6.  G proteins, adenylyl cyclase and related phosphoproteins in the developing rat heart.

Authors:  S Bartel; P Karczewski; E G Krause
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

7.  Adenylyl cyclase type 5 protein expression during cardiac development and stress.

Authors:  Che-Lin Hu; Rachna Chandra; Hui Ge; Jayashree Pain; Lin Yan; Gopal Babu; Christophe Depre; Kousaku Iwatsubo; Yoshihiro Ishikawa; Junichi Sadoshima; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-04       Impact factor: 4.733

Review 8.  Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies.

Authors:  Rachna Sadana; Carmen W Dessauer
Journal:  Neurosignals       Date:  2008-10-24

9.  Vidarabine, an anti-herpesvirus agent, prevents catecholamine-induced arrhythmias without adverse effect on heart function in mice.

Authors:  Kenji Suita; Takayuki Fujita; Wenqian Cai; Yuko Hidaka; Huiling Jin; Rajesh Prajapati; Masanari Umemura; Utako Yokoyama; Motohiko Sato; Björn C Knollmann; Satoshi Okumura; Yoshihiro Ishikawa
Journal:  Pflugers Arch       Date:  2018-02-16       Impact factor: 3.657

10.  Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment.

Authors:  Stephanie J Nakano; Juliana Sucharov; Robert van Dusen; Mackenzie Cecil; Karin Nunley; Sean Wickers; Anis Karimpur-Fard; Brian L Stauffer; Shelley D Miyamoto; Carmen C Sucharov
Journal:  J Card Fail       Date:  2016-07-15       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.